Subscribe to our Newsletters !!
In molecular biology, the LAMP (Loop-Mediated Isot
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
Drugs Controller General of India (DCGI) has led Serum Institute of India to suspend until further orders new recruitment in stage 2 and 3 clinical trials of the Oxford COVID-19 vaccine candidate in the backdrop of pharma giant AstraZeneca pausing the trials in different countries.
In an order, a copy of which was obtained by PTI, DCGI Dr V G Somani on Friday also led Serum Institute of India (SII) to increase the safety monitoring of the subjects already vaccinated as part of this trial, and submit the plan and report.
Somani also requested the firm to submit clearance from Data and Safety Monitoring Board (DSMB) from the UK as well as in India to obtain clearance from his office (DCGI) before resumption of future recruitment in the trial.
The central drug regulator DCGI had issued a show-cause notice to SII on September 9 for not informing it about AstraZeneca pausing clinical trials of this vaccine candidate in other countries and also for not submitting casualty evaluation of the”reported severe adverse events.”
After which the Pune-based firm,which has partnered with the British-Swedish biopharmaceutical giant AstraZeneca for manufacturing the Oxford vaccine candidate,on Thursday said it is pausing the clinical trials in India.
Earlier this week, AstraZeneca said it had paused the trials because of’an unexplained illness’ in a participant in the study.
“We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials,” SII said in a statement on Thursday.
According to the DCGI’s order issued on Friday, the SII in its reply stated that DSMB has noted no safety concerns from the Indian research (part 1-phase-2 research ) with the initial dose and seven days post vaccination safety data.
In its response, SII also said that DSMB further recommended”to pause additional enrolment into the study until continuing investigations of SAE reported in the united kingdom analysis is completed and the host and the UK DSMB are satisfied that it doesn’t pose any safety concerns.”
“In the view of the above, I Dr V G Somani, Drugs Controller General of India, Central Licensing Authority, after careful examination of your reply and the recommendations of the DSMB in India, in exercise of the powers vested under Rule 30 of the New Drugs and Clinical Trials Rules, 2019, direct to you suspend any new recruitment in the phase 2 and 3 clinical trial until further orders,” the order read.
“Increase the safety monitoring of these subjects already vaccinated with the vaccine under trial and submit the plan and report,” the order further stated.
On August 2, the DCGI had granted permission to the Pune-based SII to conduct Stage 2 and 3 human clinical trials of the coronavirus vaccine candidate.
AstraZeneca, the biopharmaceutical giant in a tie-up together with the Oxford University to produce the vaccine, described the pause of trials as a”pattern” one after what was”an unexplained illness.”
